CD38 and Miyoshi myopathy: Due to the NP barrier and the superior MM cell-targeting ability, we speculated that CD38-S3I-NP would possess a higher maximal tolerable dose and lower incidences of adverse effects compared to S3I-NP and free S3I-1757.